Stay updated with breaking news from Capmatinib Tabrecta. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Total revenues of $881 million in the first quarter – Jakafi® net product revenues of $572 million in Q1'24, total paid patients increased +5% Y/Y; reiterating full year 2024 guidance of...
Fifty-seven percent of drugs granted accelerated approval for a cancer indication showed clinical benefit in confirmatory studies.
– Total revenues of $919 million in the third quarter – Jakafi® net product revenues of $636 million in Q3'23, $1.9 billion YTD 2023, driven by growth in total patients across all...
WILMINGTON, Del.--(BUSINESS WIRE)--Aug 1, 2023--
Incyte (Nasdaq:INCY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency’s (EMA) has issued a positive opinion that recommends granting marketing authorization for capmatinib (Tabrecta®) as a monotherapy for the treatment of adults with advanced non-small cell lung cancer (NSCLC) harboring alterations leading to mesenchymalepithelial-transition factor gene (MET) exon 14 (METex14) skipping who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.